Quaternary Ammonium Compounds for Pulmonary Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current muscarinic receptor antagonists for treating pulmonary disorders like COPD and asthma have significant systemic side effects and require frequent dosing due to short duration of action, leading to inconvenient treatment regimens and potential non-compliance.
Innovation Solution
Development of novel quaternary ammonium compounds with improved binding affinity for muscarinic receptor subtypes, longer receptor half-lives, and higher potency, which can be administered once daily or weekly, reducing systemic side effects such as dry mouth and constipation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If inhaled muscarinic receptor antagonists are administered to treat pulmonary disorders, then bronchoprotective effects are achieved, but systemic side effects such as dry mouth, mydriasis and cardiovascular side effects occur due to absorption into systemic circulation
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (quaternary ammonium compounds with particular substituent patterns) that confer selective affinity for pulmonary muscarinic receptors while reducing systemic absorption. The structural modifications at specific positions of the molecule create localized properties that enhance pulmonary selectivity and reduce systemic side effects.
2Speed
If inhaled muscarinic receptor antagonists with short duration of action are used, then rapid onset of bronchoprotective effects is achieved, but frequent dosing is required which leads to patient non-compliance
Solution Approach 1:
The patent applies parameter changes by systematically varying molecular parameters such as substituent types, chain lengths, and structural configurations of the quaternary ammonium compounds. These parameter modifications optimize the balance between onset speed and duration of action, enabling once-daily or once-weekly dosing while maintaining rapid bronchoprotective effects.
3Productivity
If muscarinic receptor antagonists are administered by inhalation, then direct pulmonary effect is achieved, but significant absorption into systemic circulation occurs resulting in side effects
Solution Approach 1:
The patent applies the intermediary principle by using specially designed quaternary ammonium compounds as mediators that facilitate pulmonary receptor binding while acting as a barrier to systemic absorption. The molecular structure serves as an intermediary that allows selective interaction with pulmonary muscarinic receptors while minimizing entry into systemic circulation, thereby reducing side effects.
Data Source
AI summary
The invention provides compounds of the formula: (I) in salt or zwitterionic form or a pharmaceutically acceptable salt thereof, wherein R1-6, a, Z and Q are as defined in the specification. These compounds are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes for preparing such compounds and methods of using such compounds to, for example, treat pulmonary disorders such as chronic obstructive pulmonary disease and asthma.